ADX-324 Dose Level 1

Phase 3

ADX-324 Dose Level 1 is one of 5 therapeutic programs targeting Hereditary Angioedema (HAE). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Hereditary Angioedema (HAE)Recruiting

Hereditary Angioedema (HAE)Phase 3

Recruiting

Competition

Competitive Landscape

5 competitors in Hereditary Angioedema (HAE)

#DrugCompanyPhaseTrials

Dawnzera (autoinjector)

Ionis Pharmaceuticals

Phase 3

1 2

Deucrictibant

PPharvaris Netherlands B.V.

Phase 3

1 3

ADX-324

AADARx Pharmaceuticals, Inc.

Phase 3

1 4

Navenibart

AAstria Therapeutics, Inc.

Phase 3

2 5

ADX-324 Dose Level 1

AADARx Pharmaceuticals, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 3Recruiting

Hereditary Angioedema (HAE)

NCT07428499

Clinical

Trials by Indication[1]

Hereditary Angioedema (HAE)1 trial

A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

Recruiting·AADARx Pharmaceuticals, Inc.·Phase 3·NCT07428499·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ADX-324 Dose Level 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for ADX-324 Dose Level 1. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — ADARx Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AADARx Pharmaceuticals, Inc.

ADX-324 Dose Level 1

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Hereditary Angioedema (HAE)1 trial

References

Drug Info

Quick Facts

Related News